Abstract
This study aimed to analyze the evolution in the incorporation of psychotropics into National List of Essential Medicines (Relação Nacional de Medicamentos Essenciais - RENAME) and whether the current list meets the burden of mental disorders in Brazil. Requests for psychotropics sent to National Commission for the Incorporation of Technologies in the SUS (Comissão Nacional de Incorporação de Tecnologias no SUS - CONITEC) between 2012 and December 2024 were collected and the number of psychotropics for mental disorders in the last eight versions of RENAME was analyzed, as compared to the World Health Organization (WHO) list. Next, the relationship between the number of psychotropics in RENAME 2024 and the burden of disease in Brazil according to the DALY indicator was analyzed. Eleven requests for psychotropics were sent to CONITEC, equivalent to 1.0% of the total, while 90.9% of the demands referred to the incorporation and 9.1% to the expansion of use. Between 2010 and 2014, an increase was observed in the incorporation of psychotropics in RENAME, but the following RENAMEs were not changed. RENAME 2024 includes 18 psychotropics, and 66.7% are funded by the Basic Component. There is a disproportionate relationship between the number of medications for anxiety and depression in RENAME and the high burden of these diseases in Brazil. The findings indicate that the lack of review of RENAME may be impacting the mental health needs of the Brazilian population.

This publication has 19 references indexed in Scilit: